ILLUMINA, INC. Enters Proteomics Market with Strategic Acquisition

Illumina, Inc. has completed a landmark acquisition, integrating the aptamer-based and functional proteomics business from Standard BioTools Inc. This strategic move propels Illumina beyond its core genomics offerings, positioning the company in the complementary and rapidly expanding field of proteomics.

---

1. Acquisition Overview

On January 30, 2026, Illumina finalized its acquisition of Standard BioTools Inc.'s proteomics assets for $350 million in cash. This transaction, first announced on June 22, 2025, integrates key entities like SomaLogic and Sengenics. Illumina now owns their advanced aptamer-based and functional proteomics technologies.

The agreement also outlines potential future payments: up to $75 million in performance-based milestones over the next three years, linked to specific revenue targets and product development achievements. Additionally, Illumina will pay ongoing royalties on future sales of the acquired products. Notably, Illumina acquired only the proteomics segment, excluding Standard BioTools' mass cytometry and microfluidics businesses.

The acquired technologies are highly advanced. SomaLogic's SOMAscan platform, for instance, offers high-throughput and high-sensitivity capabilities, measuring thousands of proteins simultaneously from a single sample. Sengenics' KREX platform complements this by focusing on autoantibody profiling. These powerful platforms are essential for understanding disease mechanisms, identifying biomarkers, and accelerating drug discovery.

2. Strategic Rationale: Why Proteomics?

Illumina, a global leader in genomics (the study of DNA), is strategically expanding into proteomics (the study of proteins). Proteins are the functional workhorses of cells; understanding their dynamics is critical for a complete picture of human health and disease. This acquisition drives Illumina's vision to lead in "multi-omics," a field that integrates insights from genomics, proteomics, and other biological data to offer a more comprehensive view of biological systems.

This expansion allows Illumina to provide researchers and clinicians with a more complete solution. It enables them to correlate genetic predispositions with actual protein expression and function. Analysts estimate the proteomics market represents a multi-billion dollar opportunity. This acquisition positions Illumina to capture a significant share, diversifying its revenue streams and strengthening its competitive advantage in the broader life sciences industry.

3. Significance for Illumina and the Market

• Market Expansion: This acquisition propels Illumina into the rapidly growing proteomics market, which analysts project will exceed $50 billion by the end of the decade. This significantly expands Illumina's addressable market beyond genomics.
• Enhanced Portfolio: Illumina's product portfolio now offers integrated genomic and proteomic solutions, providing researchers with powerful tools for drug discovery, biomarker identification, and precision medicine.
• Substantial Investment: The $350 million cash outlay, alongside potential future payments, represents a significant investment for Illumina. This underscores its commitment to this strategic direction and its confidence in the long-term potential of multi-omics.
• Competitive Landscape: This move intensifies competition within the proteomics space. It positions Illumina against established players like Olink, Seer, Thermo Fisher Scientific, and Agilent Technologies, potentially driving further innovation across the industry.

4. Impact on Stakeholders

• Employees: Illumina will welcome approximately 200 employees from SomaLogic and Sengenics, who bring specialized expertise in proteomics. Successfully integrating these teams and cultures will be crucial.
• Customers: Existing Illumina customers will gain access to advanced proteomics tools. Meanwhile, SomaLogic and Sengenics customers will benefit from Illumina's global sales, support, and R&D infrastructure.
• Investors: This acquisition represents a significant investment and a potential new growth engine. Investors will closely monitor the integration process and market adoption of the new offerings.
• Competitors: Illumina's entry into proteomics, as a well-resourced player, will likely reshape competitive dynamics and accelerate innovation across the industry.

5. Forward Look and Key Risks

Illumina's immediate priority is the seamless integration of SomaLogic and Sengenics' technologies, sales channels, and R&D teams into its existing operations. Key challenges include harmonizing technology platforms, retaining critical talent, and ensuring a smooth transition for customers.

The acquisition's success hinges on Illumina's ability to:

• Realize Synergies: Effectively cross-sell proteomics products to its vast genomics customer base and vice-versa.
• Drive Innovation: Combine R&D efforts to develop integrated multi-omics solutions.
• Achieve Financial Targets: Generate significant revenue growth from the proteomics segment and achieve a favorable return on its investment (ROIC).

Potential risks include integration complexities, higher-than-anticipated integration costs, slower-than-expected market adoption of combined offerings, intense competition, and potential dilution of focus from Illumina's core genomics business.

6. Investor Takeaways

For investors, this acquisition signals Illumina's long-term strategic pivot toward becoming a comprehensive multi-omics solutions provider.

• Monitor Key Metrics: Investors should watch for updates on proteomics revenue contribution, gross margins of the acquired products, integration progress reports, and any new product launches or partnerships. Pay close attention to management's guidance on the acquisition's financial impact in future earnings calls.
• Long-Term Growth vs. Short-Term Volatility: While this move presents significant long-term growth opportunities, the market may experience short-term volatility as it assesses integration challenges and the pace of market adoption.
• Execution is Paramount: The ultimate success of this strategic expansion will depend heavily on Illumina's execution of the integration plan and its ability to effectively commercialize the combined multi-omics portfolio. Investors should evaluate whether Illumina can successfully translate this substantial investment into sustainable revenue growth and enhanced profitability.